Research programme: T cell-based therapeutics - Opus Bio

Drug Profile

Research programme: T cell-based therapeutics - Opus Bio

Alternative Names: CAR T-cell based therapies; CAR+ T; Chimeric antigen receptor T cell therapies; LG 690

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Medical University of South Carolina; Opus Bio; University of Pennsylvania
  • Class CAR-T cell therapies
  • Mechanism of Action Apoptosis stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Leukaemia; Lymphoma; Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Leukaemia in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lymphoma in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top